tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lava Therapeutics price target lowered to $2 from $6 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Lava Therapeutics (LVTX) to $2 from $6 and keeps a Buy rating on the shares after management decided to discontinue LAVA-1207 program, given that it did not meet the company’s internal efficacy threshold in the Phase 1 study. While “disappointed” by management’s decision to discontinue LAVA-1207, the firm remains confident in the therapeutic potential of the Gammabody platform.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1